Amgen is conducting a Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of XXXXXXXXXXX in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #20210145

Incyte is conducting a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXXXXXX in Participants with Moderate to Severe Hidradenitis Suppurativa

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #  INCB- 54707-301

Acrotech is conducting an Open-label Study to Assess the Long-Term Safety of XXXXXXXX Ointment in Mild to Moderate Atopic Dermatitis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # MEDI-MM36-302

Eli Lilly is conducting a US-Based Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab (Taltz)

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #  I1F-MC-B018

Eli Lilly is conducting an Open-Label Study of XXXXXXXXXX in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # J2T-MC-KGBP